The JCCP has received several expressions of concern relating to the supply and prescribing of unlicensed botulinum toxins such as ‘Botulax’ from Korea. In response, the JCCP Clinical Advisory Group has reviewed the position of all relevant regulators with a view to outlining a common position as the basis for this statement. This paper has been subject to review by statutory regulators including MHRA, GMC and NMC.

To read our press release click here